Published online 7 August 2006
Nucleic Acids Research, 2006, Vol. 34, No. 13 e98
© 2006 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.
Methods Online |
Simultaneous amplification and screening of whole plasmids using the T7 bacteriophage replisome
BioHelix Corporation 32 Tozer Road, Beverly, MA 01915, USA 1 New England Biolabs 240 County Road, Ipswich, MA 01938, USA
*To whom correspondence should be addressed. Tel: +1 978 998 7496; Fax: +1 978 927 3382; Email: kimh{at}biohelix.com
Received May 9, 2006. Revised July 13, 2006. Accepted July 13, 2006.
This study describes a novel helicase-mediated isothermal DNA amplification method that exponentially amplifies circular DNAs. The circular helicase-dependent amplification (cHDA) system is based on the T7 replication machinery, which includes the processive T7 helicase, an exonuclease-deficient T7 DNA polymerase (T7 Sequenase) and the T7 Gp2.5 single-stranded DNA-binding (SSB) protein. After the duplex DNA template is unwound by the T7 helicase, specific primers anneal to the separated DNA strands and T7 Sequenase extends the 3' end of each primer by a rolling circle mechanism to amplify not only a region defined by the primers but also continuous concatemers of the template. The cHDA reaction can be carried out at one temperature (25°C) for the entire process and can achieve up to 10 000-fold amplification. Amplification can be performed using purified plasmid DNA or a crude cell lysate and can amplify inserts as large as 10 kb. Following a cHDA reaction, the amplified products can be used directly for sequencing and restriction enzyme digestion without further purification. By utilizing the helicase enzyme, circular DNA samples can be simultaneously screened and amplified at one constant temperature in one easy step.
Present address: Ann Kays, Agencourt Bioscience Corporation, 500 Cumming Center Suite 2450, Beverly, MA 01915, USA
The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors